Shandong Sito Bio-technology Co., Ltd. (300583.SZ)
CNY 22.9
(-0.82%)
CNY 22.9
(-0.82%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 115.59 Million CNY | -6.56% |
| 2022 | 123.7 Million CNY | -24.5% |
| 2021 | 163.85 Million CNY | -14.5% |
| 2020 | 191.64 Million CNY | 31.16% |
| 2019 | 146.11 Million CNY | 874.13% |
| 2018 | 15 Million CNY | 0.0% |
| 2017 | - CNY | -100.0% |
| 2016 | 157.67 Million CNY | 12.63% |
| 2015 | 140 Million CNY | 40.0% |
| 2014 | 100 Million CNY | 121.27% |
| 2013 | 45.19 Million CNY | 0.0% |
| 2012 | - CNY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 79.76 Million CNY | -32.79% |
| 2024 Q2 | 63.8 Million CNY | -21.12% |
| 2024 Q3 | 51.86 Million CNY | -9.7% |
| 2023 Q3 | 143.99 Million CNY | 13.79% |
| 2023 Q4 | 115.59 Million CNY | -19.72% |
| 2023 FY | 115.59 Million CNY | -6.56% |
| 2023 Q1 | 120.68 Million CNY | -2.45% |
| 2023 Q2 | 126.53 Million CNY | 4.85% |
| 2022 FY | 123.7 Million CNY | -24.5% |
| 2022 Q4 | 123.7 Million CNY | -18.54% |
| 2022 Q3 | 151.86 Million CNY | -3.2% |
| 2022 Q2 | 156.88 Million CNY | 0.95% |
| 2022 Q1 | 155.4 Million CNY | -5.16% |
| 2021 FY | 163.85 Million CNY | -14.5% |
| 2021 Q3 | 187.78 Million CNY | -1.75% |
| 2021 Q4 | 163.85 Million CNY | -12.75% |
| 2021 Q2 | 191.12 Million CNY | 0.32% |
| 2021 Q1 | 190.51 Million CNY | -0.59% |
| 2020 FY | 191.64 Million CNY | 31.16% |
| 2020 Q1 | 145.07 Million CNY | -0.71% |
| 2020 Q2 | 140.55 Million CNY | -3.12% |
| 2020 Q3 | 88.05 Million CNY | -37.35% |
| 2020 Q4 | 191.64 Million CNY | 117.64% |
| 2019 Q2 | 80 Million CNY | -5.88% |
| 2019 FY | 146.11 Million CNY | 874.13% |
| 2019 Q4 | 146.11 Million CNY | 82.65% |
| 2019 Q1 | 85 Million CNY | 466.67% |
| 2019 Q3 | 80 Million CNY | 0.0% |
| 2018 Q1 | - CNY | 0.0% |
| 2018 Q2 | 30 Million CNY | 0.0% |
| 2018 Q3 | 30 Million CNY | 0.0% |
| 2018 FY | 15 Million CNY | 0.0% |
| 2018 Q4 | 15 Million CNY | -50.0% |
| 2017 Q1 | - CNY | -100.0% |
| 2017 Q2 | - CNY | 0.0% |
| 2017 Q3 | - CNY | 0.0% |
| 2017 Q4 | - CNY | 0.0% |
| 2017 FY | - CNY | -100.0% |
| 2016 Q2 | 224.78 Million CNY | 0.0% |
| 2016 Q1 | - CNY | -100.0% |
| 2016 Q4 | 157.67 Million CNY | 0.0% |
| 2016 Q3 | - CNY | -100.0% |
| 2016 FY | 157.67 Million CNY | 12.63% |
| 2015 Q4 | 140 Million CNY | 0.0% |
| 2015 FY | 140 Million CNY | 40.0% |
| 2014 FY | 100 Million CNY | 121.27% |
| 2013 FY | 45.19 Million CNY | 0.0% |
| 2012 FY | - CNY | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Lifecome Biochemistry Co.,Ltd. | 527 Million CNY | 78.065% |
| Chengdu Kanghua Biological Products Co., Ltd. | -6.19 Million CNY | 1964.546% |
| NanHua Bio-medicine Co., Ltd | 13 Million CNY | -789.034% |
| Porton Pharma Solutions Ltd. | 1.07 Billion CNY | 89.2% |
| Zhejiang Wecome Pharmaceutical Company Limited | 163.13 Million CNY | 29.138% |
| Guangdong VTR Bio-Tech Co., Ltd. | 1.00 CNY | -11559726500.0% |